23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Vertex Pharmaceuticals Incorporated › 2025-2026

Vertex Pharmaceuticals Incorporated 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Vertex Pharmaceuticals Incorporated’s Form 8-K, filed May 13, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 15Reported items
  • 1,193Asset managers, any item
  • 17,676Fund votes
  • May 13, 2026Meeting date

Results at a glance

Meeting of May 13, 2026: 14 items on Vertex Pharmaceuticals Incorporated’s Form 8-K, filed May 13, 2026: 4 approved · 10 passed (calculated).

Dissent

High dissent: 1 shareholder proposal (57.0% support).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Vertex Pharmaceuticals Incorporated in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Vertex Pharmaceuticals Incorporated

These tallies are Vertex Pharmaceuticals Incorporated’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 13, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Vertex Pharmaceuticals Incorporated — official shareholder meeting results, meeting held May 13, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Sangeeta Bhatia 221,280,1731,624,14193,322 --10,337,217 99.3%Passed (calculated)—
Elect Director: Lloyd Carney 213,048,5509,855,36993,717 --10,337,217 96%Passed (calculated)—
Elect Director: Alan Garber 219,396,4523,506,60494,580 --10,337,217 98%Passed (calculated)—
Elect Director: Reshma Kewalramani 221,911,160999,30687,170 --10,337,217 99.6%Passed (calculated)—
Elect Director: Michel Lagarde 220,336,3432,566,48594,808 --10,337,217 99%Passed (calculated)—
Elect Director: Jeffrey Leiden 220,333,7632,576,63887,235 --10,337,217 99%Passed (calculated)—
Elect Director: Diana McKenzie 221,316,5901,590,04790,999 --10,337,217 99.3%Passed (calculated)—
Elect Director: Bruce Sachs 209,717,81513,186,26593,556 --10,337,217 94%Passed (calculated)—
Elect Director: Jennifer Schneider 221,301,6701,602,68693,280 --10,337,217 99.3%Passed (calculated)—
Elect Director: Nancy Thornberry 220,320,9922,583,89592,749 --10,337,217 99%Passed (calculated)—
Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 223,514,0709,597,395223,388 --0 96%Approved—
Based upon the following votes, the shareholders approved, on an advisory basis, the 2025 compensation program for the Company's named executive officers 207,918,84314,522,776556,017 --10,337,217 93%Approved—
Based upon the following votes, the shareholders approved the Company's 2026 Stock and Option Plan. 216,097,2686,523,460376,908 --10,337,217 97%Approved—
Based upon the following votes, the shareholders approved a shareholder proposal regarding shareholder right to act by written consent 126,892,69695,756,148348,792 --10,337,217 57%Approved—

Source: Vertex Pharmaceuticals Incorporated, Form 8-K, filed with the SEC on May 13, 2026 — read the filing on EDGAR.

How asset managers voted at the Vertex Pharmaceuticals Incorporated 2025-2026 meeting

1,193 asset managers disclosed a vote on at least one Vertex Pharmaceuticals Incorporated item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Vertex Pharmaceuticals Incorporated’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

Elect Director: Sangeeta Bhatia

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 221,280,173AGAINST: 1,624,141

Prior year: 99.1% for (May 14, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Sangeeta Bhatia

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Sangeeta Bhatia”): 221,280,173 for, 1,624,141 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,698,226 for, 160,009 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,698,226AGAINST: 160,009ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Sangeeta Bhatia” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,3689 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Lloyd Carney

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 213,048,550AGAINST: 9,855,369

Prior year: 96.0% for (May 14, 2025 meeting) ▼ 0.5 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Lloyd Carney

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Lloyd Carney”): 213,048,550 for, 9,855,369 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,170,041 for, 688,193 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,170,041AGAINST: 688,193ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Lloyd Carney” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,822,87120,505 00For
BlackRock9,501,2622,792 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,217550 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,205197 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Alan Garber

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 219,396,452AGAINST: 3,506,604

Prior year: 98.2% for (May 14, 2025 meeting) ▲ 0.2 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Alan Garber

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Alan Garber”): 219,396,452 for, 3,506,604 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,664,904 for, 193,331 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,664,904AGAINST: 193,331ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Alan Garber” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,35918 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Reshma Kewalramani

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 221,911,160AGAINST: 999,306

Prior year: 99.8% for (May 14, 2025 meeting) ▼ 0.2 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Reshma Kewalramani

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Reshma Kewalramani”): 221,911,160 for, 999,306 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,851,637 for, 6,597 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,851,637AGAINST: 6,597ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Reshma Kewalramani” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,3724 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Michel Lagarde

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 220,336,343AGAINST: 2,566,485

Prior year: 98.7% for (May 14, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Michel Lagarde

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Michel Lagarde”): 220,336,343 for, 2,566,485 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,851,628 for, 6,607 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,851,628AGAINST: 6,607ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Michel Lagarde” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,36314 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Jeffrey Leiden

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 220,333,763AGAINST: 2,576,638

Prior year: 97.6% for (May 14, 2025 meeting) ▲ 1.2 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Jeffrey Leiden

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Jeffrey Leiden”): 220,333,763 for, 2,576,638 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,670,250 for, 187,985 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,670,250AGAINST: 187,985ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Jeffrey Leiden” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,36413 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,69323 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Diana McKenzie

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 221,316,590AGAINST: 1,590,047

Prior year: 99.3% for (May 14, 2025 meeting) unchanged

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Diana McKenzie

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Diana McKenzie”): 221,316,590 for, 1,590,047 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,846,668 for, 11,567 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,846,668AGAINST: 11,567ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Diana McKenzie” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,3725 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Bruce Sachs

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 209,717,815AGAINST: 13,186,265

Prior year: 93.5% for (May 14, 2025 meeting) ▲ 0.5 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Bruce Sachs

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Bruce Sachs”): 209,717,815 for, 13,186,265 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,459,294 for, 398,941 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,459,294AGAINST: 398,941ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Bruce Sachs” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,31562 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,67244 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Jennifer Schneider

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 221,301,670AGAINST: 1,602,686

Prior year: 99.6% for (May 14, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Jennifer Schneider

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Jennifer Schneider”): 221,301,670 for, 1,602,686 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,835,472 for, 22,763 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,835,472AGAINST: 22,763ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Jennifer Schneider” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,3725 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Elect Director: Nancy Thornberry

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 5 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 220,320,992AGAINST: 2,583,895

Prior year: 98.7% for (May 14, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 205 asset managers

Description as filed by funds: Election of Directors: Nancy Thornberry

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Elect Director: Nancy Thornberry”): 220,320,992 for, 2,583,895 against, per its Form 8-K filed May 13, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 205 asset managers below reported 123,846,659 for, 11,576 against, 19,989 abstained, 206 not voted.

FOR
FOR: 123,846,659AGAINST: 11,576ABSTAIN: 19,989NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Nancy Thornberry” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,36314 00For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 205 asset managers. All 205 are in the interactive database (link above).

Election of Directors: Suketu Upadhyay

No official matchDIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

99.9% of fund votes cast · no official result

FORABSTAIN
Details: votes by 104 asset managers

The 104 asset managers below reported 7,945,855 for, 6,595 against, 12,107,639 abstained, 206 not voted. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 7,945,855AGAINST: 6,595ABSTAIN: 12,107,639NOT VOTED: 206
Largest asset managers voting on “Election of Directors: Suketu Upadhyay” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
BlackRock11,5060 9,492,5480Abstain
Vanguard2,219,2902 1,0110For
Charles Schwab1,860,7670 00For
Loomis Sayles00 1,084,6870Abstain
HARBOR FUNDS688,1240 00For
Prudential/PGIM517,1960 00For
Jackson National25,2900 470,1260Mixed
Hartford463,4020 00For
MASTER INVESTMENT PORTFOLIO00 391,4430Abstain
ADVISORS' INNER CIRCLE FUND384,4110 00For
Bridge Builder Trust138,9510 153,5630Mixed
Transamerica217,7730 00For
Six Circles Trust00 196,3130Abstain
NEOS ETF Trust167,8740 00For
Global X137,7820 00For
Russell Investments109,7210 00For
John Hancock00 107,3090Abstain
Calamos99,9470 00For
Brighthouse87,9560 00For
Cardano Risk Management B.V.84,4220 00For
VanEck ETF Trust75,3600 00For
Pacer Funds Trust71,4400 00For
Natixis00 71,2440Abstain
Gateway Trust00 64,8790Abstain
SEI58,1860 00For

Showing the 25 largest of 104 asset managers. All 104 are in the interactive database (link above).

Based upon the following votes, the shareholders approved the Company's 2026 Stock and Option Plan.

Official resultCAPITAL STRUCTUREReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%
FOR: 216,097,268AGAINST: 6,523,460
Details: description as filed, official tally, votes by 227 asset managers

Description as filed by funds: Approval of 2026 Stock and Option Plan.

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Proposal 4: Based upon the following votes, the shareholders approved the Company's 2026 Stock and Option Plan.”): 216,097,268 for, 6,523,460 against — passed, per its Form 8-K filed May 13, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 4 : Based upon the following votes, the shareholders approved the Company's 2026 Stock and Option Plan.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 227 asset managers below reported 123,745,888 for, 521,834 against, 2 abstained, 206 not voted.

FOR
FOR: 123,745,888AGAINST: 521,834ABSTAIN: 2NOT VOTED: 206
Largest asset managers voting on “Approval of 2026 Stock and Option Plan.” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,34630 20For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,7160 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century275,000351,607 00Mixed
Prudential/PGIM503,87953,979 00Mixed
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Showing the 25 largest of 227 asset managers. All 227 are in the interactive database (link above).

Based upon the following votes, the shareholders approved, on an advisory basis, the 2025 compensation program for the…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 22 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 207,918,843AGAINST: 14,522,776

Prior year: 92.5% for (May 14, 2025 meeting) ▲ 1.0 pts

Details: description as filed, official tally, votes by 1,188 asset managers

Description as filed by funds: Advisory vote to approve named executive officer compensation.

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Proposal 3: Based upon the following votes, the shareholders approved, on an advisory basis, the 2025 compensation program for the Company's named executive officers:”): 207,918,843 for, 14,522,776 against — passed, per its Form 8-K filed May 13, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 : Based upon the following votes, the shareholders approved, on an advisory basis, the 2025 compensation program for the Company's named executive officers:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Vertex Pharmaceuticals Incorporated’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Say on Pay” (4 managers, 629 for, 210 against); “Compensation” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 196 asset managers voting on “Advisory vote to approve named executive officer compensation.” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,843,31362 20For
BlackRock9,504,0540 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,67244 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price964,7689,899 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,4020 00For

Fund voting reports, all 196 managers: 123,487,547 for, 231,846 against, 19,991 abstained, 1,206 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 1,030 asset managers voting on “Advisory vote to approve named executive officer compensation.” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group30,487,1550 00For
Capital Research Global Investors21,018,9280 00For
BlackRock11,604,7311,105 810For
PARAMETRIC PORTFOLIO ASSOCIATES LLC10,821,6000 00For
Invesco8,477,1070 00For
State Street7,541,05775,297 00For
GEODE CAPITAL MANAGEMENT, LLC6,117,7250 00For
Janus Henderson4,263,7908,750 00For
Loomis Sayles3,387,219134,712 00For
AllianceBernstein3,406,7430 00For
Wellington3,038,8190 00For
JENNISON ASSOCIATES LLC2,696,3073,063 00For
Clearbridge Investments, LLC2,657,135620 00For
Vanguard2,616,5470 00For
Northern Trust2,223,38022,756 00For
T. Rowe Price2,210,83728,566 00For
UBS01,926,752 00Against
Charles Schwab1,926,0460 00For
Winslow Capital Management, LLC1,835,8980 00For
Amundi01,805,464 00Against
Goldman Sachs1,417,5750 00For
MELLON INVESTMENTS Corp1,368,7020 00For
Fidelity1,329,2080 00For
Victory Capital1,254,218757 00For
Legal & General Investment Management Ltd32,3731,144,946 00Against

Institutional-manager reports, all 1,030 managers: 161,818,748 for, 11,813,962 against, 429,850 abstained, 47,219 not voted, 640 unknown. Showing the 25 largest; every one is in the interactive database (link above).

Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 8 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 223,514,070AGAINST: 9,597,395

Prior year: 97.1% for (May 14, 2025 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 209 asset managers

Description as filed by funds: Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending December 31, 2026.

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Proposal 2: Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026:”): 223,514,070 for, 9,597,395 against — passed, per its Form 8-K filed May 13, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 : Based upon the following votes, the shareholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 209 asset managers below reported 123,758,546 for, 120,672 against, 22,989 abstained, 206 not voted.

FOR
FOR: 123,758,546AGAINST: 120,672ABSTAIN: 22,989NOT VOTED: 206
Largest asset managers voting on “Ratification of Ernst & Young LLP as independent Registered Public Accounting firm for the year ending Decembe” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard23,822,87220,504 00For
BlackRock9,502,5941,460 00For
Invesco7,233,0830 00For
Fidelity6,487,4760 00For
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street3,068,67244 00For
JPMorgan3,042,9930 00For
Charles Schwab1,860,7670 00For
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles1,084,6870 00For
TIAA1,072,5560 00For
Legg Mason1,030,8520 00For
Victory Capital1,023,3580 00For
JANUS INVESTMENT FUND993,5710 00For
T. Rowe Price974,6670 00For
HARBOR FUNDS688,1240 00For
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century626,6070 00For
Prudential/PGIM557,8580 00For
Dimensional495,8350 00For
Jackson National495,4160 00For
Hartford463,205197 00For

Showing the 25 largest of 209 asset managers. All 209 are in the interactive database (link above).

Based upon the following votes, the shareholders approved a shareholder proposal regarding shareholder right to act by…

Official resultSHAREHOLDER RIGHTS AND DEFENSESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

57% Approved · of votes cast

FOR 57%AGAINST
FOR: 126,892,696AGAINST: 95,756,148
Details: description as filed, official tally, votes by 204 asset managers

Description as filed by funds: Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written consent.

Vertex Pharmaceuticals Incorporated’s own tally for this item (“Proposal 5: Based upon the following votes, the shareholders approved a shareholder proposal regarding shareholder right to act by written consent:”): 126,892,696 for, 95,756,148 against — passed, per its Form 8-K filed May 13, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 5: Based upon the following votes, the shareholders approved a shareholder proposal regarding shareholder right to act by written consent:”
Support: 57% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 204 asset managers below reported 67,039,531 for, 56,834,832 against, 19,991 abstained, 206 not voted.

FORAGAINST
FOR: 67,039,531AGAINST: 56,834,832ABSTAIN: 19,991NOT VOTED: 206
Largest asset managers voting on “Shareholder proposal, if properly presented at the meeting, regarding shareholder right to act by written cons” at Vertex Pharmaceuticals Incorporated, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Capital Group36,479,8650 00For
Vanguard1,862,59021,980,785 20Mixed
BlackRock13,5379,490,517 00Against
Invesco6,870,069363,014 00Mixed
Fidelity71,3636,416,113 00Against
INVESTMENT CO OF AMERICA6,269,1420 00For
AMCAP FUND4,621,2670 00For
State Street6,7323,061,984 00Against
JPMorgan03,042,993 00Against
Charles Schwab5501,860,217 00Against
Columbia Threadneedle1,386,7890 00For
NEW ECONOMY FUND1,320,7510 00For
Loomis Sayles01,084,687 00Against
TIAA01,072,556 00Against
Legg Mason1,030,8520 00For
Victory Capital944,96478,394 00Mixed
JANUS INVESTMENT FUND1,743991,828 00Against
T. Rowe Price0974,667 00Against
HARBOR FUNDS0688,124 00Against
AB LARGE CAP GROWTH FUND INC645,0940 00For
American Century275,000351,607 00Mixed
Prudential/PGIM38,020519,838 00Mixed
Dimensional0495,835 00Against
Jackson National401,06594,351 00Mixed
Hartford463,4020 00For

Showing the 25 largest of 204 asset managers. All 204 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of May 14, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest Vertex Pharmaceuticals Incorporated shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 254,163,953 shares outstanding at the time of that meeting.

Fund voting reports: top Vertex Pharmaceuticals Incorporated shareholders by shares voted on “Advisory vote to approve named executive officer compensation.”, 2025-2026
#Asset manager % of shares outstanding
1Capital Group 14.35%
2Vanguard 9.38%
3BlackRock 3.74%
4Invesco 2.85%
5Fidelity 2.55%
6INVESTMENT CO OF AMERICA 2.47%
7AMCAP FUND 1.82%
8State Street 1.21%
9JPMorgan 1.20%
10Charles Schwab 0.73%
Institutional-manager reports: top Vertex Pharmaceuticals Incorporated shareholders by shares voted on “Advisory vote to approve named executive officer compensation.”, 2025-2026
#Asset manager % of shares outstanding
1Capital Group 12.00%
2Capital Research Global Investors 8.27%
3BlackRock 4.57%
4PARAMETRIC PORTFOLIO ASSOCIATES LLC 4.26%
5Invesco 3.34%
6State Street 3.00%
7GEODE CAPITAL MANAGEMENT, LLC 2.41%
8Janus Henderson 1.68%
9Loomis Sayles 1.39%
10AllianceBernstein 1.34%

Reported Vertex Pharmaceuticals Incorporated holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Vertex Pharmaceuticals Incorporated holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Capital World Investors28,739,975 11.31%Proxy statement (DEF 14A), proxy filed April 2, 2026
BlackRock23,969,517 9.43%Form 13F, quarter ended March 31, 2026
The Vanguard Group22,281,729 8.77%Proxy statement (DEF 14A), proxy filed April 2, 2026
Capital Research Global Investors.17,319,044 6.81%Proxy statement (DEF 14A), proxy filed April 2, 2026
State Street11,730,139 4.62%Form 13F, quarter ended March 31, 2026
JPMorgan Chase7,033,156 2.77%Form 13F, quarter ended March 31, 2026
Wellington Management3,212,589 1.26%Form 13F, quarter ended March 31, 2026
Morgan Stanley3,120,310 1.23%Form 13F, quarter ended March 31, 2026
Northern Trust2,564,264 1.01%Form 13F, quarter ended March 31, 2026
Invesco2,561,057 1.01%Form 13F, quarter ended March 31, 2026

Percentages above are of 254,163,953 shares outstanding, as reported by Vertex Pharmaceuticals Incorporated on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Vertex Pharmaceuticals Incorporated's shareholder meeting held May 13, 2026, in the 2025-2026 proxy season, 1,193 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 17,676 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote to approve named executive officer compensation. — Vertex Pharmaceuticals Incorporated's filing reports the proposal as approved, with 93% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Vertex Pharmaceuticals Incorporated's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 13, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Vertex Pharmaceuticals Incorporated’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Vertex Pharmaceuticals Incorporated proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Vertex Pharmaceuticals (VRTX) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/vertex-pharmaceuticals-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.